Hong Kong Stock Market Announcement Highlights | InnoSilicon, Tuda Tong, and Changfeng Pharmaceutical Included in the Hang Seng Composite Index Constituents

LootboxPhobia · 2026-02-20T03:44:52+00:00

Yingxi Intelligent, Tuda Tong, and Changfeng Pharmaceutical are included in the Hang Seng Composite Index, while Hansoh Pharmaceutical and others received approval for new drug listings. Several companies issued profit warnings, expecting a decline in profits for the upcoming fiscal year. SUTENG Juchuang achieved sales growth in lidar products and turned a profit for the first time in Q4.

LootboxPhobia

2026-02-20 03:44:52

Abstract generation in progress

[Major Announcements]

InnoSilicon (03696) Included in the Hang Seng Composite Index Constituents

Tenda Communication (02665) Included in the Hang Seng Composite Index Constituents

Changfeng Pharmaceutical (02652) Included in the Hang Seng Composite Index Constituents

Hansoh Pharma (03692): Amlodipine Mesylate Tablets Approved for Monotherapy in the European Union

Bokang Vision Cloud-B (02592): Clinical trial application for CBT-199 has been approved, and the clinical trial is deemed safe to proceed

CSPC Pharmaceutical Group (01093): GLP-1/GIP receptor dual-agonist long-acting peptide injection approved for clinical trials in the United States

CSPC Pharmaceutical Group (01093): Ropivacaine long-acting injection (SYH9089 injection) approved for clinical trials in China

Hengrui Medicine (02696): FDA approval for Phase 1 clinical trial application of HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection for subcutaneous administration) for multiple myeloma treatment

[Financial Results]

Shougang Resources (00639) Issues Profit Warning, expects 2025 attributable consolidated profit to owners to be approximately HKD 600 million to HKD 700 million

CSPC Pharmaceutical Group (02005) Issues Profit Warning, expects 2025 attributable profit to equity holders to decrease by approximately 45% to 60% year-on-year

Goodbaby International (01086) Issues Profit Warning, expects 2025 net profit to decrease by approximately 35% to 45% year-on-year

Suteng Juchuang (02498) Continues to grow sales of LiDAR products in FY2025, achieving first quarterly profit in Q4

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.